- Home
- PETS vs RPTX Comparison
PETS vs RPTX Comparison
Compare PETS & RPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PETS
- RPTX
- Stock Information
- Founded
- PETS 1996
- RPTX 2016
- Country
- PETS United States
- RPTX Canada
- Employees
- PETS N/A
- RPTX N/A
- Industry
- PETS Retail-Drug Stores and Proprietary Stores
- RPTX Biotechnology: Pharmaceutical Preparations
- Sector
- PETS Consumer Staples
- RPTX Health Care
- Exchange
- PETS Nasdaq
- RPTX Nasdaq
- Market Cap
- PETS 70.4M
- RPTX 64.8M
- IPO Year
- PETS N/A
- RPTX 2020
- Fundamental
- Price
- PETS $3.24
- RPTX $1.50
- Analyst Decision
- PETS Sell
- RPTX Strong Buy
- Analyst Count
- PETS 2
- RPTX 3
- Target Price
- PETS $3.35
- RPTX $4.50
- AVG Volume (30 Days)
- PETS 177.2K
- RPTX 724.4K
- Earning Date
- PETS 08-12-2025
- RPTX 08-12-2025
- Dividend Yield
- PETS N/A
- RPTX N/A
- EPS Growth
- PETS N/A
- RPTX N/A
- EPS
- PETS 0.02
- RPTX N/A
- Revenue
- PETS $247,010,000.00
- RPTX $1,073,000.00
- Revenue This Year
- PETS N/A
- RPTX N/A
- Revenue Next Year
- PETS N/A
- RPTX N/A
- P/E Ratio
- PETS $189.87
- RPTX N/A
- Revenue Growth
- PETS N/A
- RPTX N/A
- 52 Week Low
- PETS $2.90
- RPTX $0.89
- 52 Week High
- PETS $6.85
- RPTX $4.07
- Technical
- Relative Strength Index (RSI)
- PETS 44.94
- RPTX 50.25
- Support Level
- PETS $3.00
- RPTX $1.50
- Resistance Level
- PETS $4.10
- RPTX $1.62
- Average True Range (ATR)
- PETS 0.22
- RPTX 0.07
- MACD
- PETS -0.02
- RPTX -0.01
- Stochastic Oscillator
- PETS 21.82
- RPTX 41.94
About PETS PetMed Express Inc.
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.
About RPTX Repare Therapeutics Inc.
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.